Recently MetaReports.net published an exhaustive research report on Neocardiogenesis, the phenomenon that is revolutionizing regenerative medicine and creating new and novel options for treatment of ischemic heart disease. Scope of that report precluded us from delving too much into areas peripheral to the primary focus of the report. Nevertheless some of those issues are very pertinent to understanding the rapidly evolving landscape of regenerative cardiology. So we decided to address those issues in brief satellite reports that supplement our research on Neocardiogenesis.

Our "Neocardiogenesis" research report was the first to address the issue of the infamous "Placebo Effect" that jeopardized the efficacy of angiogenic agents in clinical trials causing the big three of biotechnology industry - Genentech, Chiron (Novartis) and Scios (Johnson & Johnson), to back off from the business of mending broken hearts early on in the quest. Since the early departure of these protein and gene therapy based Bears in the beginning of the new millennium, the Bulls have taken over the baton and are now riding the stem cell bandwagon with renewed vigor. Fueled by California's $3 billion dollar Proposition 71, stem cell initiative and complemented by other well-funded stem cell research programs globally, regenerative cardiology is nothing less than the Gold Rush of the 21st century.

Despite the unprecedented rush for getting the first in-vivo heart repair drug to the market, the old specter of missing efficacy hasn't still stopped haunting the much awaited passage to success. Our "Neocardiogenesis" report suggested that that the missing efficacy in the published clinical studies, contrary to the popular belief, could not have been merely because of the "Placebo Effect". The current report further expands on this apparently "show stopper" issue that affects hundreds of registered clinical trials and many more still in the planning stage that are investigating various protein, gene and stem cell based therapeutic agents for treating ailing hearts.

- Identify the key factors in the current heart repair clinical trial protocols that precipitate benefit amongst the controls on placebo treatment.

- Identify the key factors in the current heart repair clinical trial protocols that attenuate efficacy of the therapeutic agent (protein, gene or stem cell) amongst the treatment groups.

- Adopt knowledge from this report to drive strategic planning for the clinical development of current and future regenerative cardiology therapies.